MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has named Hui Liu as Director of Biostatistics to bolster its efforts as the company progresses with its pivotal Phase 3 Alzheimer’s disease (AD) clinical trial.
“Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence,” said Cheng Fang, Ph.D., Senior Vice President of Research and Development. “Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move toward our goals.”
With over 19 years of experience across all phases of clinical trials, Ms. Liu brings a wealth of knowledge in statistical methodology and data analysis. Her career spans designing and interpreting complex clinical data, creating statistical analysis plans, and managing programming specifications required for regulatory filings. Beyond her technical skills, she has excelled in team leadership, strategic account management, and fostering collaboration to drive quality and efficiency.
“I’m excited to join Annovis and honored to work with a passionate and driven team,” said Ms. Liu. “I look forward to applying my statistical expertise to further enhance the integrity of the company’s clinical trials and to help generate high-quality evidence that will support scientific advancement and regulatory success.”
This appointment aims to advance Annovis Bio’s Alzheimer’s research and strengthen its capacity for delivering high-quality, data-driven findings in preparation for regulatory milestones.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.